4basebio PLC (AIM:4BB)

Market Cap	81.58M -46.5%
Revenue (ttm)	1.69M +81.5%
Net Income	-16.91M
EPS	-1.09
Shares Out	15.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19
Open	519.75
Previous Close	525.00
Day's Range	500.50 - 525.00
52-Week Range	420.00 - 1,040.00
Beta	0.90
Analysts	Buy
Price Target	1,600.00 (+204.76%)
Earnings Date	Sep 21, 2026

About 4basebio

4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modificatio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 140
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: 4BB

Financial Performance

In 2025, 4basebio's revenue was 1.69 million, an increase of 81.46% compared to the previous year's 933,000. Losses were -16.91 million, 37.1% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for 4BB stock is "Buy." The 12-month stock price target is 1,600p, which is an increase of 204.76% from the latest price.

Price Target

1,600p

(204.76% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 6, 2026

Data Sources Report a data error